Ola Landgren, MD, PhD, is a Professor and Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, New York, NY.
He undertook his medical training at the Karolinska Institutet, followed by residencies at Karolinska University Hospital and the National Cancer Institute.
Prof. Landgren’s research focuses on the development of novel treatment strategies for multiple myeloma (MM), smoldering myeloma, MGUS and related plasma cell disorders. In addition, he has a special interest in advanced disease monitoring by new measurable residual disease (MRD) assays. As one of the pioneers in the development of MRD testing in MM, he develops and implements new measurement strategies in clinical trials.
Active on social media via his Twitter, Prof. Landgren communicates hemonc updates to people around the world.
Steering Committee member for MRD Focus.
When is the optimal time to measure minimal residual disease (MRD) in myeloma patients?